Adam Cifu adamcifu
4 years 4 months ago
At a time when most American doctors have never seen measles, I think we should stop calling things morbilliform.
Dr. John Cush RheumNow
4 years 4 months ago
Differential diagnosis of dysphagia - when due to autoimmune dz is called Autoimmune neurogenic dysphagia - causes include inflammatory myopathies,inclusion body myositis, myasthenia gravis, Guillain–Barre, MS, NMO, paraneoplastic neuropathies https://t.co/oA0cPVJ5pJ https://t.co/58MyQwmxhL
Rheum Cat rheum_cat
4 years 4 months ago
⭐️Ethics of placebo-controlled trials in PsA ➡️move toward active comparator designs. Need to use measures of deeper response (e.g., ACR 50, PASI100).
⭐️Assesing safety: LTE studies not adequate. Use of phase 4 studies or observational data but beware confounding by indication
Dr. John Cush RheumNow
4 years 4 months ago
SARS-CoV-2-infected alveoli (specifically N protein-coding plasmid alone) induces IL-6 production. Also, COVID-19 Sera also induced IL-6, moreso in those w/ severe disease. anti-N Ab promotes IL-6 production & may lead to cytokine storm https://t.co/jfPNwZM0g8 https://t.co/FwIs11i2qc
Dr. John Cush RheumNow
4 years 4 months ago
Tonight!: Join us for Tuesday Night Rheumatology on Spondyloarthritis Spectrum. This webinar will feature lecture highlights followed by live audience Q & A.
7pm ET | Join on Zoom or watch LIVE on RheumNow Twitter, LinkedIn and Facebook.
https://t.co/Y6MtCItIxw https://t.co/ysRM3cWyYa
Data from Olmstead county, MN over the past four decades shows that the incidence and prevalence of systemic lupus erythematosus (SLE) is increasing.
SLE was diagnosed using the EULAR/ACR criteria and looked at patients seen between 1976–2018.
They identified a total of 188 incident SLE cases in 1976–2018 (mean age 46.3 yrs; 83% women).
Crowson and colleagues at the Mayo Clinic have shown that rheumatoid arthritis (RA) patients have a higher prevalence of multimorbidity with as many as 44 different morbidities of interest in RA.
Dr. John Cush RheumNow
4 years 4 months ago
Data from Scleroderma Lung Study (CTX vs MMF in PSS) shows that early progression of ILD by CXR scoring (≥ 2% at 12 or 24 months) experienced significantly worse long-term survival than those with stable Xrays (P = .014). https://t.co/BVy0WEE6G8 https://t.co/e6NN7nxNDt
Dr. John Cush RheumNow
4 years 4 months ago
24 week, Phase II RCT of baricitinib in 314 active #SLE patients showed significant reductions in levels of dsDNA, IgG, Sm & ACL Abs; but had no effect on C3/C4, RNP, SSA, SSB. Changes in dsDNA did not correlate with SRI-4 responses though.https://t.co/cF6rHbtvf9 https://t.co/zXnUImaLHF
Dr. John Cush RheumNow
4 years 4 months ago
FDA has approved baricitinib (Olumiant) for the Treatment of Certain Hospitalized Patients with COVID-19 who require supplemental O2, mechanical ventilation, ECMO. Rec dose: 4-mg once daily for 14 days or until hospital discharge https://t.co/RiEp01tc0v https://t.co/f3RvUAzdRp
Science Translational Medicine has published results of a Canadian study of low back pain (LBP) suggests that pain control by anti-inflammatory treatments might have negative effects on pain duration and may be counterproductive for long-term pain outcomes.
Dr. John Cush RheumNow
4 years 4 months ago
Cool NEJM Case of Spinal Gout in 82-yr-old woman with 3-wk hx of severe LBP, rigors, anorexia, incomplete urination. Hx of PsA, CKD, CHF treated w/ Humira, HCQ, diuretics. Imaging tophi in spine, responded to steroids and allopurinol. https://t.co/JgH2bPsDeu https://t.co/RAPNxohe55
UCB announced they have received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis (PSO).
Dr. John Cush RheumNow
4 years 4 months ago
New podcast available on Methotrexate Monitoring. Download wherever you get your podcasts.
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.
https://t.co/TQiUMdS4R0 https://t.co/vgejiV3hUl
Dr. John Cush RheumNow
4 years 4 months ago
Study of 198 RMD pts, vaccinated 91% JAKi and 80% MTX mono pts were Ab+ for spike protein. Adjusting MTX or JAKi did not significantly alter the immunogenicity (S1 spike Abs). DMARD adjustments w/ COVID-19 VAX may not be needed. https://t.co/ebw172M5I4 https://t.co/vjXqTbuD5t

